Alyssa Hollingsworth, PA
Physician Assistant · Mobile, ALNPI 1962085662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 888 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 888 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- plus $3K from 11 others
What the payments were for
- Food & beverage$14,17498%
- Education$2982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 220 | $3,417 |
| AbbVie | 204 | $2,355 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 98 | $2,141 |
| Alkermes, Inc. | 79 | $1,834 |
| Otsuka America Pharmaceutical, Inc. | 77 | $1,148 |
| Johnson & Johnson | 63 | $1,059 |
| Neurocrine Biosciences, Inc. | 23 | $667 |
| E.r. Squibb & Sons, L.L.C. | 39 | $508 |
| Vanda Pharmaceuticals Inc. | 22 | $470 |
| Lundbeck LLC | 26 | $350 |
| Sunovion Pharmaceuticals Inc. | 21 | $188 |
| Axsome Therapeutics, Inc. | 7 | $156 |
| Indivior Inc. | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| GSK | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $15 |
| PARI Respiratory Equipment, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$480
- ARISTADA$480
- CAPLYTA$380
- ABILIFY MAINTENA$124
- COBENFY$123
- INGREZZA$121
- REXULTI$120
- ARISTADA INITIO$120
- VRAYLAR$119
- AUSTEDO$117
How this compares
$14,472 in reported general payments places this provider in the 95th percentile of 846 physician assistant providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 315 | $934,725 |
| Austedo XrDeutetrabenazine | 55 | $414,247 |
| Abilify MaintenaAripiprazole | 58 | $153,179 |
| AristadaAripiprazole Lauroxil | 53 | $152,911 |
| IngrezzaValbenazine Tosylate | 17 | $144,611 |
| Invega TrinzaPaliperidone Palmitate | 14 | $111,165 |
| AustedoDeutetrabenazine | 12 | $83,810 |
| VraylarCariprazine Hcl | 38 | $54,082 |
| CaplytaLumateperone Tosylate | 31 | $51,924 |
| RexultiBrexpiprazole | 28 | $46,098 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $31,490 |
| TrintellixVortioxetine Hydrobromide | 11 | $9,822 |
| Aripiprazole | 197 | $9,613 |
| Paliperidone ErPaliperidone | 63 | $8,603 |
| Risperidone ErRisperidone Microspheres | 11 | $6,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,059 | $1,045,890329 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $3,417 | $498,05767 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,148 | $199,27886 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,834 | $184,40171 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $667 | $144,61117 claims |
| AbbVieVraylar | $2,355 | $54,08238 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,141 | $51,92431 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $32 | $9,82211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 physician assistant providers in Alabama.
Other physician assistant in Mobile
- Ashley PeaceMobile$27K
- Gregory SharpMobile$19K
- Elizabeth SimpsonMobile$18K
- Jessica DavisMobile$15K
- Jessica KantralesMobile$14K
- Mary HneichMobile$12K
- James GunnMobile$10K
- Taryn ThompsonMobile$10K
- Hannah SmithMobile$10K
- Megan HarrisMobile$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.